reports
EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian...
Issuer: CureVac / Key word(s): Study CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK 24.04.2024 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will as...
EQS-News: CureVac gibt Start einer kombinierten Phase-1/2-Studie zur V...
Emittent / Herausgeber: CureVac / Schlagwort(e): Studie CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit GSK 24.04.2024 / 13:03 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit GSK Phase-1-Teil einer kombinierten Phase-1/2-Studie gestartet, im Rahmen der Pandemievorsorge gegen das hoch pathogene Vogelgrippevirus (H5N1), das mögliche zukünftige...
Travere Therapeutics and CSL Vifor Announce European Commission Approv...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparse...
Form 8.3 - Apex Fundrock Limited : Form 8.3 - Tyman PLC
Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Form 8.3 - Tyman PLC 24-Apr-2024 / 11:56 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trust...
EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business O...
Issuer: CureVac / Key word(s): Personnel CureVac Appoints Thaminda Ramanayake as New Chief Business Officer 24.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, Germany/BOSTON, USA – A...
EQS-News: CureVac ernennt Thaminda Ramanayake zum neuen Chief Business...
Emittent / Herausgeber: CureVac / Schlagwort(e): Personalie CureVac ernennt Thaminda Ramanayake zum neuen Chief Business Officer 24.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac ernennt Thaminda Ramanayake zum neuen Chief Business Officer Herr Ramanayake verfügt über mehr als 15 Jahre Erfahrung in der Entwicklung von Biopharma-Unternehmen und in Geschäftsabschlüssen Er erzielte große Erfolge beim Abschluss klinischer Kooperationen, M&A, Einlizensierungen und strategischen Finanzierungsinitiativen in v...
R.E.A. Holdings plc: Notification of Major Holdings
R.E.A. Holdings plc (RE.) R.E.A. Holdings plc: Notification of Major Holdings 24-Apr-2024 / 12:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0002349065 Issuer Name R.E.A. HOLDINGS PLC UK or Non-UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Arbuthnot Latham (Nominees) Limited City of registered office (if applicable) London Country of registered office (if applicable) Un...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cance...
Rogers Communications Reports First Quarter 2024 Results
Rogers Communications Reports First Quarter 2024 Results Reports nine straight quarters of industry-leading growthReaffirms industry-leading 2024 financial guidance More Canadians continue to choose Rogers over any other carrier 124,000 postpaid mobile phone and retail Internet net addsPostpaid mobile phone net adds of 98,000, up 3,000Retail Internet net adds of 26,000, up 12,000 Delivers industry-leading growth in Cable and Wireless Total service revenue up 31%; adjusted EBITDA up 34%Wireless service revenue and adjusted EBITDA up 9% Wireless blended ARPU up...
Shenandoah Telecommunications Company to Hold its First Quarter 2024 E...
Shenandoah Telecommunications Company to Hold its First Quarter 2024 Earnings Call at 8:30 a.m. on Friday, May 3, 2024 EDINBURG, Va., April 24, 2024 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024, and will host a conference call and simultaneous webcast on the same day at 8:30 a.m. Eastern Time to discuss Shentel’s financial results and business highlights. Date: May 3, 2024Time: 8:30 AM ET Listen via Internet: For Analysts, please register to dial-in...
Smart Share Global Limited Files Its Annual Report on Form 20-F
Smart Share Global Limited Files Its Annual Report on Form 20-F SHANGHAI, April 24, 2024 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the United States Securities and Exchange Commission (the “SEC”) on April 24, 2024. The annual report can be accessed on the Company’s investor relations website at / and on the SEC’s website at The Company will provide a hard copy...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beck...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. from the recently completed monotherapy Part 1 of the study were shared in March 2024, and showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 12-weeks post-dose. Part 2 of...
Rogers Communications Declares 50 Cents per Share Quarterly Dividend
Rogers Communications Declares 50 Cents per Share Quarterly Dividend July 5, 2024 payment date following June 10, 2024 record date TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) (“Rogers”) announced that its Board of Directors declared a quarterly dividend totaling 50 cents per share (the “Quarterly Dividend”) on each of its outstanding Class B Non-Voting shares (“Class B Shares”) and Class A Voting shares. The Quarterly Dividend will be paid on July 5, 2024 to shareholders of record on June 10, 2024. Quarterly dividends are on...
IOI Properties Group Berhad: 1 director
A director at IOI Properties Group Berhad sold 19,450,000 shares at 2.104MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Inwido AB: 1 director
A director at Inwido AB maiden bought 4,300 shares at 134.080SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
CRH Announces Date for Q1 2024 Results Conference Call
DUBLIN--(BUSINESS WIRE)-- CRH plc, the leading provider of building materials solutions, will publish its Q1 2024 financial results on Friday, May 10, 2024 at 2:00 a.m. (New York) / 7:00 a.m. (Dublin) followed by a conference call and webcast presentation at 8:00 a.m. (New York) / 1:00 p.m. (Dublin). CRH's results and the related presentation will be available at . CRH invites investors and members of the public to register for the event at . Upon registration a link to join the call and dial-in details will be made available. A replay of the webcast will be available on . About CRH CR...
TransAlta Achieves Commercial Operation of 300 MW White Rock Project a...
TransAlta Achieves Commercial Operation of 300 MW White Rock Project and Increases its US Renewables Fleet to 820 MW CALGARY, Alberta, April 24, 2024 (GLOBE NEWSWIRE) -- TransAlta Corporation (“TransAlta” or the “Company”) (TSX: TA) (NYSE: TAC) announced today that the combined 300 MW White Rock East and White Rock West wind facilities (“White Rock”), located in Caddo County, Oklahoma, have achieved commercial operation. The White Rock wind facilities are fully contracted to Amazon Energy LLC (“Amazon”) and are currently supplying clean and affordable electricity to our customer. TransAlt...
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Med...
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departments SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs ac...
Treace Medical Named First Medical Device Partner and Official Foot an...
Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the court DALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Addu...
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab ...
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society Internati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.